Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

Similar articles for PubMed (Select 21775819)

1.

The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.

Nelson HH, Almquist LM, LaRocca JL, Plaza SL, Lambert-Messerlian GM, Sugarbaker DJ, Bueno R, Godleski JJ, Marsit CJ, Christensen BC, Kelsey KT.

Epigenetics. 2011 Aug;6(8):1029-34. doi: 10.4161/epi.6.8.16074. Epub 2011 Aug 1.

2.

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J.

Ann Thorac Surg. 2008 Jan;85(1):265-72; discussion 272.

PMID:
18154821
3.

Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.

Franceschini MC, Ferro P, Canessa PA, Battolla E, Dessanti P, Valentino A, Casolari L, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2014 Dec;34(12):7425-9.

PMID:
25503183
4.

Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.

Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):646-50. doi: 10.1158/1055-9965.EPI-08-0422. Epub 2009 Feb 3.

5.

Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels.

Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Bruno R, Gemignani F, Landi S.

Int J Biol Markers. 2011 Apr-Jun;26(2):117-23. doi: 10.5301/JBM.2011.8332.

PMID:
21574151
6.

Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.

Ferro P, Canessa PA, Battolla E, Dessanti P, Franceschini MC, Chiaffi L, Morabito A, Fontana V, Pezzi R, Fedeli F, Pistillo MP, Roncella S.

Anticancer Res. 2013 Jun;33(6):2707-13.

PMID:
23749930
7.

Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.

Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J.

J Thorac Oncol. 2013 Jul;8(7):947-51. doi: 10.1097/JTO.0b013e31828f696b.

PMID:
23777840
8.

Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter.

Tan K, Kajino K, Momose S, Masaoka A, Sasahara K, Shiomi K, Izumi H, Abe M, Ohtsuji N, Wang T, Hino O, Fujii H.

Hum Pathol. 2010 Sep;41(9):1330-8. doi: 10.1016/j.humpath.2010.03.002. Epub 2010 Jun 22.

PMID:
20573372
9.

Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.

Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T.

J Thorac Oncol. 2008 Nov;3(11):1317-24. doi: 10.1097/JTO.0b013e318187491c.

PMID:
18978568
10.

Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.

Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Chella A, Lucchi M, Mussi A, Foddis R.

J Thorac Oncol. 2011 Sep;6(9):1587-93. doi: 10.1097/JTO.0b013e31821e1c08.

PMID:
21642872
11.

Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.

Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P.

Am J Respir Crit Care Med. 2006 May 15;173(10):1155-60. Epub 2006 Feb 2.

PMID:
16456138
12.

Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein.

Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Bruno R, Landi D, Gemignani F, Landi S.

Occup Environ Med. 2010 Apr;67(4):233-6. doi: 10.1136/oem.2009.049205. Epub 2009 Oct 26.

PMID:
19858537
13.

Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.

Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, Rusch VW, Sadelain M, Adusumilli PS.

Clin Cancer Res. 2012 May 1;18(9):2478-89. doi: 10.1158/1078-0432.CCR-11-2614. Epub 2012 Feb 27.

14.

Soluble mesothelin-related peptides levels in patients with malignant mesothelioma.

Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M.

Dis Markers. 2012;32(2):123-31. doi: 10.3233/DMA-2011-0866.

15.

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.

Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I, Naka T.

Lung Cancer. 2008 Oct;62(1):45-54. doi: 10.1016/j.lungcan.2008.02.012. Epub 2008 Apr 3.

PMID:
18394747
16.

MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.

PLoS One. 2014 Jan 21;9(1):e85935. doi: 10.1371/journal.pone.0085935. eCollection 2014.

17.

Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.

Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K.

Lung Cancer. 2008 Aug;61(2):235-43. doi: 10.1016/j.lungcan.2007.12.025. Epub 2008 Feb 20.

PMID:
18281122
18.

Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.

Filiberti R, Marroni P, Spigno F, Merlo DF, Mortara V, Caruso P, Cioè A, Michelazzi L, Bruzzone A, Bobbio B, Simonassi C, Del Corso L, Galli R, Racchi O, Dini G, Linares R, Mencoboni M.

Oncology. 2014;86(1):33-43. doi: 10.1159/000355687. Epub 2013 Dec 21.

PMID:
24401539
19.

ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.

Cheng YY, Kirschner MB, Cheng NC, Gattani S, Klebe S, Edelman JJ, Vallely MP, McCaughan BC, Jin HC, van Zandwijk N, Reid G.

J Thorac Oncol. 2013 Oct;8(10):1317-28. doi: 10.1097/JTO.0b013e3182a0840a.

PMID:
24457242
20.

Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.

Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G.

J Clin Oncol. 2010 Jul 10;28(20):3316-22. doi: 10.1200/JCO.2009.26.9944. Epub 2010 May 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk